Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies

Table 2

Annualized bleeding rates by dosing group.

Annualized bleeding rates	Prophylaxis; 1-2x/wk; ()	Prophylaxis; ≥3x/wk; ()
All bleeds
Mean ± SD	4.1 ± 6.4	7.0 ± 10.7
Median (Q1; Q3)	2.0 (0; 4.0)	3.9 (1.5; 9.3)
Joint bleeds
Mean ± SD	2.8 ± 5.2	4.5 ± 7.0
Median (Q1; Q3)	0.9 (0; 2.6)	2.4 (0.6; 5.5)
Spontaneous bleeds
Mean ± SD	2.4 ± 5.0	3.1 ± 6.2
Median (Q1; Q3)	0 (0; 1.9)	0.9 (0; 3.7)
Trauma-related bleeds
Mean ± SD	1.6 ± 3.7	3.4 ± 5.4
Median (Q1; Q3)	0.6 (0; 2.0)	1.5 (0.5; 4.6)

Q1 = quartile 1; Q3 = quartile 3.